FilingSEC EDGAR8-K
MetaVia Announces Positive Phase 1 Interim Data for DA-1726 and Phase 2 Plans
· SEC accepted
StagePhase 1 Interim Results
Filing content
DA-1726 demonstrated a 68% placebo-adjusted reduction in liver fat and 13.5% weight reduction, with a Phase 2 study in MetALD and ALD targeted for the second half of 2027.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…